OtherClinical Investigations (Human)
Tau PET imaging with 18F-PI-2620 in patients with Alzheimer's disease and healthy controls: a first-in-human study
Andre Mueller, Santiago Bullich, Olivier Barret, Jennifer Madonia, Mathias Berndt, Caroline Papin, Audrey Perrotin, Norman Koglin, Heiko Kroth, Andrea Pfeifer, Gilles Tamagnan, John P Seibyl, Kenneth Marek, Susan de Santi, Ludger M Dinkelborg and Andrew W Stephens
Journal of Nuclear Medicine November 2019, jnumed.119.236224; DOI: https://doi.org/10.2967/jnumed.119.236224
Andre Mueller
1 Life Molecular Imaging GmbH, Germany;
Santiago Bullich
1 Life Molecular Imaging GmbH, Germany;
Olivier Barret
2 Invicro LLC, United States;
Jennifer Madonia
2 Invicro LLC, United States;
Mathias Berndt
1 Life Molecular Imaging GmbH, Germany;
Caroline Papin
1 Life Molecular Imaging GmbH, Germany;
Audrey Perrotin
1 Life Molecular Imaging GmbH, Germany;
Norman Koglin
3 Life Molecular Imaging GmbH, Germany;
Heiko Kroth
4 AC Immune SA, Switzerland;
Andrea Pfeifer
4 AC Immune SA, Switzerland;
Gilles Tamagnan
2 Invicro LLC, United States;
John P Seibyl
2 Invicro LLC, United States;
Kenneth Marek
2 Invicro LLC, United States;
Susan de Santi
5 Life Molecular Imaging Inc, United States
Ludger M Dinkelborg
1 Life Molecular Imaging GmbH, Germany;
Andrew W Stephens
1 Life Molecular Imaging GmbH, Germany;
Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Tau PET imaging with 18F-PI-2620 in patients with Alzheimer's disease and healthy controls: a first-in-human study
Andre Mueller, Santiago Bullich, Olivier Barret, Jennifer Madonia, Mathias Berndt, Caroline Papin, Audrey Perrotin, Norman Koglin, Heiko Kroth, Andrea Pfeifer, Gilles Tamagnan, John P Seibyl, Kenneth Marek, Susan de Santi, Ludger M Dinkelborg, Andrew W Stephens
Journal of Nuclear Medicine Nov 2019, jnumed.119.236224; DOI: 10.2967/jnumed.119.236224
Tau PET imaging with 18F-PI-2620 in patients with Alzheimer's disease and healthy controls: a first-in-human study
Andre Mueller, Santiago Bullich, Olivier Barret, Jennifer Madonia, Mathias Berndt, Caroline Papin, Audrey Perrotin, Norman Koglin, Heiko Kroth, Andrea Pfeifer, Gilles Tamagnan, John P Seibyl, Kenneth Marek, Susan de Santi, Ludger M Dinkelborg, Andrew W Stephens
Journal of Nuclear Medicine Nov 2019, jnumed.119.236224; DOI: 10.2967/jnumed.119.236224
Jump to section
Related Articles
Cited By...
- Cortical Tau Aggregation Patterns associated with Apraxia in Alzheimer's Disease
- One-Year Longitudinal Changes in Tau Accumulation on [18F]PI-2620 PET in the Alzheimer Spectrum
- [18F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration
- Fibril Paint to detect Amyloids and determine Fibril Length
- PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimers Disease With machine learning: the PREVIEW study protocol
- Individual regional associations between A{beta}-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies
- Stacked binding of a small molecule PET tracer to Alzheimers tau paired helical filaments
- Multimodality Imaging in Primary Progressive Aphasia
- An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-PBB3 (18F-APN-1607)
- Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimers Disease Continuum
- TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
- In vivo visualization of propagating {alpha}-synuclein pathologies in mouse and marmoset models by a bimodal imaging probe, C05-05
- Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers
- Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of 18F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain